These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36298537)

  • 1. Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose.
    Gareayaghi N; Demirci M; Ozbey D; Dasdemir F; Dinc HO; Balkan II; Saribas S; Saltoglu N; Kocazeybek B
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.
    Puthanakit T; Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Sophonphan J; Meepuksom T; Jupimai T; Sodsai P; Anugulruengkitt S; Hirankarn N;
    Vaccine X; 2022 Dec; 12():100211. PubMed ID: 36059600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines.
    Atıcı S; Soysal A; Gönüllü E; Aydemir G; Öner N; Alan S; Engin H; Yıldız M; Karaböcüoğlu M
    Rev Soc Bras Med Trop; 2023; 56():e00462023. PubMed ID: 37493731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of Booster.
    do Nascimento TA; Nogami PY; de Oliveira CF; Neto WFF; da Silva CP; Ribeiro ACS; de Sousa AW; Freitas MNO; Chiang JO; Silva FA; das Chagas LL; Carvalho VL; Azevedo RSS; Vasconcelos PFC; Costa IB; Costa IB; Barbagelata LS; das Chagas Junior WD; da Penha Junior ET; Soares LS; Viana GMR; Amarilla AA; Modhiran N; Watterson D; Casseb LMN; Martins LC; Henriques DF
    Vaccines (Basel); 2024 Jul; 12(7):. PubMed ID: 39066430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
    Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Could Prior COVID-19 Affect the Neutralizing Antibody after the Third BNT162b2 Booster Dose: A Longitudinal Study.
    Erdem MG; Unlu O; Buber S; Demirci M; Kocazeybek BS
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
    Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
    BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.
    Low EV; Tok PSK; Husin M; Suah JL; Tng BH; Thevananthan T; Appannan MR; Yahaya H; Mohd Zin S; Muhamad Zin F; Sivasampu S; Peariasamy KM
    JAMA Netw Open; 2022 Aug; 5(8):e2226046. PubMed ID: 35947381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
    Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey.
    Çağlayan D; Süner AF; Şiyve N; Güzel I; Irmak Ç; Işik E; Appak Ö; Çelik M; Öztürk G; Alp Çavuş S; Ergör G; Sayiner A; Ergör A; Demiral Y; Kiliç B
    J Med Virol; 2022 May; 94(5):2212-2221. PubMed ID: 35075655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
    Yavuz E; Günal Ö; Başbulut E; Şen A
    J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in China.
    Jiang H; Jin P; Guo X; Zhu J; Wang X; Wan P; Wan J; Liu J; Li J; Zhu F
    Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.
    Rammauro F; Carrión F; Olivero-Deibe N; Fló M; Ferreira A; Pritsch O; Bianchi S
    Vaccine; 2022 Aug; 40(35):5189-5196. PubMed ID: 35907676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
    Grenfell RFQ; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; Lourenço AJ; Martins-Filho OA; de Oliveira JG; Teixeira-Carvalho A; Campos GRF; Nogueira ML; Alves PA; Fernandes GR; Castilho LR; Lima TM; de Abreu DPB; Alvim RGF; Silva TBS; Jeremias WJ; Otta DA; Campi-Azevedo AC;
    Front Immunol; 2022; 13():918896. PubMed ID: 35757764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study.
    Wen GP; Zhu M; Li LR; Li XJ; Ye HM; Zhou YL
    Front Immunol; 2023; 14():1099629. PubMed ID: 36817474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactogenicity and immunogenicity of the intradermal administration of BNT162b2 mRNA vaccine in healthy adults who were primed with an inactivated SARS-CoV-2 vaccine.
    Temtanakitpaisan Y; Saengnipanthkul S; Sarakosol N; Maskasame S; Mongkon S; Buranrat B; Thammawat S; Patamatamkul S; Nernsai P
    Vaccine X; 2022 Dec; 12():100242. PubMed ID: 36415450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
    Shehab M; Alrashed F; Alfadhli A; Alsayegh A; Aldallal U; Alsayegh M; Cherian P; Alkhair I; Thanaraj TA; Channanath A; Dashti AA; Albanaw A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
    Front Med (Lausanne); 2022; 9():933996. PubMed ID: 35860742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of adaptive immune responses in healthcare workers who received a Coronavirus disease 2019 vaccine booster dose.
    Klinmalai C; Srisala S; Sahakijpicharn T; Apiwattanakul N
    Health Sci Rep; 2024 Jul; 7(7):e2250. PubMed ID: 39015422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees.
    Masson LC; Servian CDP; Jardim VH; Dos Anjos D; Dorta ML; Batalha-Carvalho JV; Moro AM; Romão PRT; Souza M; Fiaccadori FS; Fonseca SG
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.